PARP1 and cancer: PARP inhibition leads to increased accumulation of SSBs that cannot be repaired and are converted into DSBs, which need to be repaired by HR; however, in HR-deficient cancer cells, DSBs cannot be repaired by this pathway, leading to a significant increase in genomic instability, with the newly formed DSBs becoming lethal for the cell [153].